NanoViricides' anti-viral drug FluCide-I safe for animals, study shows

By Angela McDaniels

Seattle, Nov. 7 - NanoViricides Inc. said the major constituent of its anti-viral drug FluCide-I caused no toxic symptoms or ill effects in laboratory animals during initial safety studies.

More studies are being conducted for further detailed evaluations at the Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School.

The company said it will follow these studies with pre-clinical evaluations of molecules designed to target the drug to the Avian flu and common influenza viruses.

NanoViricides said it believes current government efforts to prepare for a potential flu pandemic could result in significantly shortened regulatory approval of FluCide-I in later phases, should the drug prove successful in pre-clinical trials.

NanoViricides is based in West Haven, Conn. and develops special-purpose nanomaterials for anti-viral therapy.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.